#1 Clinical Trials Search in Europe

Cytarabine

Cytarabine, also known as cytosine arabinoside or Ara-C, is a chemotherapy drug commonly used in the treatment of acute myeloid leukemia (AML). This article explores various clinical trials investigating the use of cytarabine in different dosages, combinations, and treatment schedules for AML patients. These studies aim to improve treatment outcomes, reduce side effects, and enhance the quality of life for individuals battling this aggressive blood cancer.

Table of Contents

What is Cytarabine?

Cytarabine is a chemotherapy drug widely used in the treatment of various blood cancers. It is known by several other names, including:

  • ARA-C
  • Arabinofuranosylcytosine
  • Arabinosylcytosine
  • Cytosar-U
  • Cytosine arabinoside
These alternative names may be used by your healthcare provider or in medical literature.[2]

How Cytarabine Works

Cytarabine belongs to a class of drugs called antimetabolites. It works by interfering with the DNA synthesis of cancer cells, which prevents them from dividing and growing. This action helps to stop the spread of cancer cells in the body.[1]

Conditions Treated with Cytarabine

Cytarabine is primarily used to treat various types of blood cancers, including:

  • Acute Myeloid Leukemia (AML): This is the most common condition treated with cytarabine. AML is a type of cancer that affects the blood and bone marrow.[1]
  • Myelodysplastic Syndromes (MDS): These are a group of disorders where the bone marrow doesn’t produce enough healthy blood cells.[3]
  • Acute Lymphoblastic Leukemia (ALL): Although less common, cytarabine can also be used in some cases of ALL, another type of blood cancer.[4]

How Cytarabine is Administered

Cytarabine can be administered in several ways, depending on the specific treatment plan:

  • Intravenous (IV) infusion: The drug is given directly into a vein over a period of time. This is the most common method for high-dose treatments.[1]
  • Subcutaneous injection: The drug is injected under the skin. This method is often used for lower doses or in outpatient settings.[5]
  • Continuous infusion: In some cases, cytarabine may be given as a continuous IV infusion over several days.[6]
The dosage and schedule of cytarabine can vary widely depending on the specific condition being treated, the patient’s overall health, and other factors. Your healthcare team will determine the most appropriate regimen for your situation.

Cytarabine in Combination Therapies

Cytarabine is often used in combination with other chemotherapy drugs to enhance its effectiveness. Some common combinations include:

  • Cytarabine + Daunorubicin: This combination is frequently used in the treatment of AML.[5]
  • Cytarabine + Idarubicin: Another combination used in AML treatment, sometimes considered more potent than the daunorubicin combination.[5]
  • Cytarabine + Fludarabine: This combination is used in some AML treatment protocols, especially for older patients.[7]
  • Cytarabine + Etoposide: Used in some consolidation therapy regimens for AML.[4]
These combinations are designed to target cancer cells through multiple mechanisms, potentially improving treatment outcomes.

Potential Side Effects

Like all chemotherapy drugs, cytarabine can cause side effects. Some common side effects may include:

  • Lowered blood counts (which can increase risk of infection, anemia, and bleeding)
  • Nausea and vomiting
  • Diarrhea
  • Mouth sores
  • Hair loss
  • Fatigue
Your healthcare team will monitor you closely for these and other potential side effects and can provide treatments to help manage them.[5]

Ongoing Clinical Trials

Researchers continue to study cytarabine to find new ways to use it more effectively and with fewer side effects. Some areas of ongoing research include:

  • Combining cytarabine with newer targeted therapies, such as sorafenib, to potentially improve outcomes in AML.[3]
  • Using cytarabine in combination with azacitidine, another drug that affects DNA, in older patients with AML.[6]
  • Exploring low-dose cytarabine combinations, such as with arsenic trioxide, for elderly patients who may not tolerate standard high-dose chemotherapy.[8]
These clinical trials aim to improve treatment outcomes and quality of life for patients with blood cancers.

Trial Focus Key Findings/Objectives Patient Population
Low-dose cytarabine plus arsenic trioxide Exploring feasibility for elderly AML patients; assessing overall response rate and survival Patients aged 60+ with comorbidities
Comparison of anthracyclines (daunorubicin vs idarubicin) with cytarabine Evaluating efficacy and safety of different anthracycline combinations; studying maintenance with IL-2 AML patients aged 50-70 years
Outpatient high-dose cytarabine consolidation Assessing safety, cost-effectiveness, and quality of life compared to inpatient administration Older AML patients in remission
Risk-oriented postremission strategies Comparing autologous stem cell transplantation vs blood stem cell-supported high-dose cytarabine Adult AML patients based on risk classification
Idarubicin dosage optimization with cytarabine Comparing 8 mg/m2 vs 10 mg/m2 idarubicin doses for induction therapy efficacy and safety Newly diagnosed AML patients
Accelerated high-dose cytarabine consolidation Evaluating safety of administering HiDAC on days 1-3 vs standard days 1, 3, and 5 AML patients aged 61+ in complete remission

FAQ

  • What is cytarabine and how is it used in AML treatment? Cytarabine is a chemotherapy drug used to treat acute myeloid leukemia (AML). It works by interfering with DNA synthesis in cancer cells, preventing them from growing and dividing. In AML treatment, cytarabine is often used in combination with other drugs during induction therapy to achieve remission and in consolidation therapy to maintain remission.
  • What are the different dosages of cytarabine used in clinical trials? Clinical trials have explored various dosages of cytarabine, including standard-dose (100-200 mg/m2 per day) and high-dose (1-2 g/m2 per dose) regimens. Some studies have investigated low-dose cytarabine (20 mg/m2 per day) for older or frail patients. The dosage and schedule may vary depending on the specific trial and patient characteristics.
  • How is cytarabine administered to patients? Cytarabine is typically administered intravenously (IV) in a hospital setting. The duration and frequency of administration can vary depending on the treatment protocol. For example, it may be given as a continuous infusion over several days or as intermittent doses every 12 hours. Some trials have also explored subcutaneous administration for certain patient groups.
  • What are the potential side effects of cytarabine treatment? Common side effects of cytarabine include low blood cell counts (neutropenia, thrombocytopenia, anemia), increased risk of infections, fatigue, nausea, vomiting, and hair loss. High-dose cytarabine can also cause neurological side effects such as coordination problems or confusion. The severity and duration of side effects can vary depending on the dosage and individual patient factors.
  • How do clinical trials aim to improve cytarabine-based treatments for AML? Clinical trials are exploring various strategies to enhance cytarabine-based treatments, including: optimizing dosage and administration schedules, combining cytarabine with new targeted therapies or immunotherapies, investigating outpatient administration for certain regimens, and developing risk-adapted treatment approaches based on patient characteristics and disease features. The goal is to improve efficacy, reduce side effects, and enhance overall outcomes for AML patients.

Ongoing Clinical Trials on Cytarabine

  • Venetoclax plus drug combination versus drug combination alone in children with relapsed acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

  • Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Italy The Netherlands Sweden

  • Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +7

  • Study of Blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Estonia +11

  • Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Greece Hungary +4

  • Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland

  • Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Greece Hungary Italy +2

  • Study of L-Annamycin and Cytarabine for Adults with Refractory or Relapsed Acute Myeloid Leukemia

    Recruiting

    4 1 1
    Investigated drugs:
    Belgium Czechia France Germany Italy Lithuania +3

  • Study on the Safety of Eganelisib Alone and with Cytarabine for Patients with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Acute Myeloid Leukemia (AML): A type of blood cancer that starts in the bone marrow and quickly moves into the blood. It affects the myeloid cells, which normally develop into various types of blood cells.
  • Cytarabine: A chemotherapy drug used to treat various types of blood cancers, especially acute myeloid leukemia. It is also known as cytosine arabinoside or Ara-C.
  • Induction therapy: The first phase of treatment for AML, aimed at killing as many leukemia cells as possible to achieve remission.
  • Consolidation therapy: Treatment given after remission is achieved, intended to kill any remaining cancer cells and prevent relapse.
  • Remission: A state in which the signs and symptoms of cancer have decreased or disappeared, although cancer may still be present in the body.
  • High-dose cytarabine (HiDAC): A treatment regimen using higher doses of cytarabine, typically 1-2 grams per square meter of body surface area.
  • Neutropenia: A condition characterized by an abnormally low number of neutrophils (a type of white blood cell) in the blood, increasing the risk of infections.
  • Thrombocytopenia: A condition in which there is a lower than normal number of platelets in the blood, which can lead to easy bruising and bleeding.
  • Allogeneic stem cell transplantation: A procedure in which a person receives blood-forming stem cells from a genetically similar, but not identical, donor.
  • Event-free survival (EFS): The length of time after treatment during which no adverse events (such as disease progression or relapse) are detected.

References

  1. https://clinicaltrials.gov/study/NCT00428558
  2. https://clinicaltrials.gov/study/NCT00096122
  3. https://clinicaltrials.gov/study/NCT00516828
  4. https://clinicaltrials.gov/study/NCT00002800
  5. https://clinicaltrials.gov/study/NCT00931138
  6. https://clinicaltrials.gov/study/NCT01067274
  7. https://clinicaltrials.gov/study/NCT02319135
  8. https://clinicaltrials.gov/study/NCT00850304